32 results
8-K
EX-99.1
SPRY
ARS Pharmaceuticals Inc
21 Mar 24
ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4:06pm
costs and stock-based compensation, partially offset by a decrease in license milestone expenses.
G&A Expenses: General and administrative expenses were
8-K
EX-10.1
9ppyg02v
8 Nov 22
ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
4:51pm
DEFM14A
iu6p0mzmxm h30g4ac04
6 Oct 22
Proxy related to merger
4:16pm
PRER14A
4n7y25bwrzour
16 Sep 22
Preliminary revised proxy
4:56pm
PRER14A
4d1om6j2ozb0z
16 Sep 22
Preliminary revised proxy
4:56pm
PREM14A
0k1hin1z0wuxbqier
11 Aug 22
Preliminary proxy related to merger
5:22pm
PREM14A
io73l
11 Aug 22
Preliminary proxy related to merger
5:22pm
10-Q
3mfd2my
13 May 21
Quarterly report
4:21pm